Validating benefit of biomarker-directed therapy for acute kidney injury: can you have your cake and eat it?

J R Prowle^{1

2}, M Schetz³

Affiliations

¹ Adult Critical Care Unit and Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London, E1 1BB, UK. j.prowle@qmul.ac.uk.
² William Harvey Research Institute, Queen Mary University of London, London, UK. j.prowle@qmul.ac.uk.
³ Division of Cellular and Molecular Medicine, Clinical Department and Laboratory of Intensive Care Medicine, KU Leuven University, Herestraat 49, 3000, Leuven, Belgium.

Editorial

J R Prowle et al. Intensive Care Med. 2017 Apr.

. 2017 Apr;43(4):578-580.

doi: 10.1007/s00134-017-4710-7. Epub 2017 Feb 16.

J R Prowle^{1

2}, M Schetz³

¹ Adult Critical Care Unit and Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London, E1 1BB, UK. j.prowle@qmul.ac.uk.
² William Harvey Research Institute, Queen Mary University of London, London, UK. j.prowle@qmul.ac.uk.
³ Division of Cellular and Molecular Medicine, Clinical Department and Laboratory of Intensive Care Medicine, KU Leuven University, Herestraat 49, 3000, Leuven, Belgium.

No abstract available

Comment on

Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial.
Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A. Meersch M, et al. Intensive Care Med. 2017 Nov;43(11):1551-1561. doi: 10.1007/s00134-016-4670-3. Epub 2017 Jan 21. Intensive Care Med. 2017. PMID: 28110412 Free PMC article. Clinical Trial.